Adjuvants are vaccine components that enhance the magnitude, breadth and durability of
the immune response. Following its introduction in the 1920s, alum remained the only …

The clinical success of immune checkpoint therapy (ICT) has produced explosive growth in
tumor immunology research because ICT was discovered through basic studies of immune …

Dendritic cells (DCs) develop in the bone marrow from haematopoietic progenitors that have
numerous shared characteristics between mice and humans. Human counterparts of mouse …

Dendritic cells (DCs) play a central role in the regulation of the balance between CD8 T cell
immunity vs. tolerance to tumor antigens. Cross-priming, a process which DCs activate CD8 …

Dendritic cells (DC) are professional antigen presenting cells, uniquely able to induce naïve
T cell activation and effector differentiation. They are, likewise, involved in the induction and …

Since the discovery of MHC molecules, it has taken 40 years to arrive at a coherent picture
of how MHC class I and MHC class II molecules really work. This is a story of the proteases …

In vitro-transcribed messenger RNA-based therapeutics represent a relatively novel and
highly efficient class of drugs. Several recently published studies emphasize the potential …

Dying cells have an important role in the initiation of CD8+ T cell-mediated immunity. The
cross-presentation of antigens derived from dying cells enables dendritic cells to present …

Classical dendritic cells (cDCs) form a critical interface between innate and adaptive
immunity. As myeloid immune cell sentinels, cDCs are specialized in the sensing of …

During the process of cross-presentation, viral or tumor-derived antigens are presented to
CD8+ T cells by Batf3-dependent CD8α+/XCR1+ classical dendritic cells (cDC1s). We …